We congratulate Gingras et al. for their report on regional node irradiation (RNI) in the human epidermal growth factor receptor 2 (HER2)–targeted therapy era (1). They suggest that RNI has no impact on disease-free survival (DFS) in node-positive (N+), HER2-positive breast cancer (BC) patients treated with conservative surgery, axillary node dissection (ALND), and whole breast irradiation. These results reported in the anti-HER2 era contradict RNI data from the MA20 and EORTC22922 trials (2,3).

中文翻译：

---

RE：早期HER2阳性乳腺癌的保乳手术后的局部淋巴结照射：ALTTO试验的亚分析结果

我们祝贺Gingras等人。他们关于人类表皮生长因子受体2（HER2）靶向治疗时代的区域淋巴结照射（RNI）的报告（1）。他们认为，RNI对结节阳性（N +），HER2阳性乳腺癌（BC）接受保守手术，腋窝淋巴结清扫（ALND）和全乳照射的患者的无病生存期（DFS）没有影响。抗HER2时代报道的这些结果与MA20和EORTC22922试验的RNI数据相矛盾（2,3）。